Metabolic Syndrome By: Dr.AP.Ahmed el-Shaer Dr.Mohamed El-Zayat.

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

M ETABOLIC S YNDROME IN P ERIONIAL D IALYSIS Dr. Sreelatha Calicut.
Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema Effect of renin-angiotensin system blockade on calcium.
Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
Metabolic Syndrome Symposium Dar Al-Kalima Health and Wellness Center Bethlehem, Palestine Oct
Metabolic Complications of HIV Dr Lou Haenel, Jr Endocrinology 12/10.
Hypertension – Summary
Antidiabetic Drugs Until 1994, FDA-approved antidiabetics Insulin and Sulfonylurea Last few years, the list was expanding Insulin (different preparations.
Type 2 Diabetes Mellitus Aetiology, Pathogenesis, History, and Treatment.
T2DM MANAGEMENT DENTAL COURSE Mohamed AlMaatouq, MD King Khalid University Hospital King Saud University.
Linked Metabolic Abnormalities:
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Diabetes Mellitus Dr. Meg-angela Christi Amores. Diabetes Mellitus refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
LONG TERM BENEFITS OF ORAL AGENTS
M ETABOLIC S YNDROME By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
DIABETES MELLITUS THERAPY. Nutrition Therapy  Weight loss frequently is a primary goal of nutrition therapy because 80% to 90% of people with type II.
METABOLIC Syndrome: a Global Perspective
Criteria for Diagnosis of DM * Testing must be repeated on separate day. FPG is the preferred test ** Symptoms of DM IFG = Impaired fasting glucose IGT.
Diabetes Mellitus Diabetes Mellitus is a group of metabolic diseases characterized by elevated levels of glucose in blood (hyperglycemia) Diabetes Mellitus.
Diabetes in Elderly Adults. By the age of 75, approximately 20% of the population are afflicted with this illness.. By the age of 75, approximately 20%
Amber Leon Jeanine Mills Erin Prasad Nutrition Assessment and Therapy 1 Winter 2012.
Oral Hypoglycemic Drugs
CARDIOVASCULAR MODULE: HYPERTENSION Adult Medical-Surgical Nursing.
cardio protection: Focus on
VBWG Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology.
Oral hypoglycemic drugs
PPAR gamma system and glucose: metabolism. Shared metabolic abnormalities with insulin resistance and endothelial dysfunction Glucotoxicity Lipotoxicity.
Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
Epidemiology and Diagnosis A Practical Guide to Therapy Monotherapy Combination Therapy Add ons.
Hypertension By Alexandre Sloukgi.
Diabetes and Obesity and Aging ~20% of men and women over 65 years have type 2 diabetes (ADA criteria). ~24% in this age group have diabetes according.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 50 Diabetes Mellitus and the Metabolic Syndrome.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Metabolic Syndrome Dr. Hasan AYDIN. Metabolic Syndrome Clustering of cardiovascular risk factors Central obesity Diabetes Hypertension Dyslipidemia.
Type 2 diabetes mellitus in the older patient Shokoufeh Bonakdaran Associate Professor of Endocrinology Mashhad university of medical sciences.
นพ. เฉลิมศักดิ์ สุวิชัย โรงพยาบาล พะเยา. Management of Type 2 Diabetes Mellitus: A New Paradigm Approach Dr. Chalermsak Suwichai Phayao Hospital.
Dr :Reem Murad.  Syndrome X  Cardiometabolic Syndrome  Cardiovascular Dysmetabolic Syndrome  Insulin-Resistance Syndrome  Metabolic Syndrome  Beer.
Oral hypoGLYCEMICS.
Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
Utilizing Anti-diabetic Agents to Manage Cardiovascular Disease in T2DM Patients James LaSalle, D.O., FAAFP.
Diabetes mellitus typus 2 in primary care
(Syndrome X, Insulin Resistance syndrome)
Endocrine Block 1 Lecture Dr. Usman Ghani
Chapter 7 Metabolic syndrome
Lecture on Anti Diabetic Drugs
Diabetes Mellitus Nursing Management.
The Diabetes
Diabetes Mellitus Nursing Management.
By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology
Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.
Diagram representing the renin–angiotensin–aldosterone system
Oral hypoglycemic drugs
Endocrine Block 1 Lecture Dr. Usman Ghani
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
Effect of Metabolic Surgery on diabetes and hypertension
Subclinical organ damage Treatment LVH
המשותף לכל סוגי הסוכרת היפרגליקמיה כרונית.
Diabetic Disorders 4th Leading cause of deaths in the US
Vascular biology of metabolic syndrome
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
Category Hypertension Normal < 130/< 85 Recheck in 2 years. High Normal 130–139/ 85–89 Recheck in 1 year Hypertension Stage 1 (mild) 140–159/90–99.
CHD RISK Glycemia 75g OGTT Time Metabolic Syndrome
Sulphonylureas and Glitazones In spite of the big number of anti-diabetic factors obtainable.
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
Prepared by :Dr. Latifa Mari’e
Presentation transcript:

Metabolic Syndrome By: Dr.AP.Ahmed el-Shaer Dr.Mohamed El-Zayat

Definition :

Pathophysiology of Metabolic Syndrome 1-Central (Visceral) Obesity 2-Insulin Resistance 3-Atherogenic Dyslipidemia 4-Hypertension 5-Thrombogenicity 6-Inflammation and Endothelial Dysfunction

Systemic Effects of Metabolic Syndrome Diabetes Acute stroke in the elderly. kidney Liver Pregnancy Surgical patient

Insulin Resistance

Strategies for Metabolic Management -Insulin Resistance and Hyperglycemia: A) Insulin secretagogues Sulfonylureas Nonsulfonylureas (repaglinide and nateglinide) B)Insulin-sensitizing agents Biguanides (metformin) PPAR- ligands (thiazolidinediones) -Atherogenic Dyslipidemia: HMG-CoA reductase inhibitors (statins) PPAR- ligands (fibrates) -Increased Blood Pressure: Inhibitors of the renin – angiotensin system B-Blockers Calcium channel antagonists

Exercise and Mobilization Nutrition

Anesthesia and Analgesia Volatile anesthetics Intravenous induction agents Opioids Neuraxial blockade

Thank you

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.